Jim Simons’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-165,151
| Closed | -$2.67M | – | 3487 |
|
|
2025
Q4 | $2.67M | Buy |
+165,151
| New | +$2.19M | ﹤0.01% | 1689 |
|
|
2024
Q2 | – | Sell |
-243,484
| Closed | -$2.89M | – | 3752 |
|
|
2024
Q1 | $2.89M | Buy |
243,484
+201,184
| +476% | +$2.68M | ﹤0.01% | 1790 |
|
|
2023
Q4 | $518K | Sell |
42,300
-26,800
| -39% | -$244K | ﹤0.01% | 2750 |
|
|
2023
Q3 | $665K | Sell |
69,100
-73,828
| -52% | -$754K | ﹤0.01% | 2570 |
|
|
2023
Q2 | $1.29M | Buy |
142,928
+62,328
| +77% | +$575K | ﹤0.01% | 2310 |
|
|
2023
Q1 | $634K | Sell |
80,600
-13,700
| -15% | -$102K | ﹤0.01% | 2756 |
|
|
2022
Q4 | $637K | Sell |
94,300
-29,800
| -24% | -$160K | ﹤0.01% | 2804 |
|
|
2022
Q3 | $1.8M | Sell |
124,100
-105,270
| -46% | -$1.47M | ﹤0.01% | 2081 |
|
|
2022
Q2 | $2.26M | Buy |
229,370
+212,570
| +1,265% | +$2.34M | ﹤0.01% | 2103 |
|
|
2022
Q1 | $248K | Sell |
16,800
-5,627
| -25% | -$80.8K | ﹤0.01% | 3552 |
|
|
2021
Q4 | $297K | Sell |
22,427
-1,101
| -5% | -$17.5K | ﹤0.01% | 3347 |
|
|
2021
Q3 | $411K | Buy |
+23,528
| New | +$477K | ﹤0.01% | 2960 |
|
|
2021
Q2 | – | Sell |
-153,428
| Closed | -$3.94M | – | 3633 |
|
|
2021
Q1 | $3.94M | Buy |
153,428
+104,000
| +210% | +$2.73M | ﹤0.01% | 1800 |
|
|
2020
Q4 | $939K | Buy |
+49,428
| New | +$848K | ﹤0.01% | 2528 |
|
|
2020
Q3 | – | Sell |
-41,346
| Closed | -$500K | – | 3524 |
|
|
2020
Q2 | $500K | Sell |
41,346
-6,182
| -13% | -$65.7K | ﹤0.01% | 2876 |
|
|
2020
Q1 | $364K | Buy |
+47,528
| New | +$641K | ﹤0.01% | 2900 |
|
|
2019
Q4 | – | Sell |
-19,028
| Closed | -$221K | – | 3627 |
|
|
2019
Q3 | $221K | Buy |
+19,028
| New | +$307K | ﹤0.01% | 3119 |
|
|
2019
Q2 | – | Sell |
-159,929
| Closed | -$4.58M | – | 3655 |
|
|
2019
Q1 | $4.58M | Sell |
159,929
-19,300
| -11% | -$418K | ﹤0.01% | 1859 |
|
|
2018
Q4 | $3.54M | Buy |
179,229
+61,880
| +53% | +$1.24M | ﹤0.01% | 1948 |
|
|
2018
Q3 | $2.6M | Buy |
117,349
+81,621
| +228% | +$1.1M | ﹤0.01% | 2154 |
|
|
2018
Q2 | $290K | Sell |
35,728
-7,700
| -18% | -$68K | ﹤0.01% | 2973 |
|
|
2018
Q1 | $412K | Sell |
43,428
-45,300
| -51% | -$474K | ﹤0.01% | 2972 |
|
|
2017
Q4 | $865K | Buy |
+88,728
| New | +$923K | ﹤0.01% | 2721 |
|
|
2016
Q4 | – | Sell |
-17,337
| Closed | -$112K | – | 3350 |
|
|
2016
Q3 | $112K | Buy |
+17,337
| New | +$131K | ﹤0.01% | 3164 |
|
Other funds holding KALV
VA
FLSM
SCM
TCM
SCM
Jim Simons's KALV Position: Q1 2026 in Review
Jim Simons sold out of KalVista Pharmaceuticals (KALV) in Q1 2026, closing a stake of 165,151 shares — an estimated $2.67M sold.
Jim Simons first reported a position in KALV in Q3 2016 and held it in 24 quarters. The position peaked at $4.58M in Q1 2019. 184 funds tracked by Wall St. Rank hold KALV as of Q1 2026.
- Jim Simons reported no remaining KalVista Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Jim Simons sold 165,151 KalVista Pharmaceuticals shares in Q1 2026, an estimated $2.67M.
- Jim Simons first reported a position in KalVista Pharmaceuticals in Q3 2016 and held it in 24 quarters.
- Jim Simons's KalVista Pharmaceuticals position peaked at $4.58M in Q1 2019.
- 184 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.